184 related articles for article (PubMed ID: 17395712)
1. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins.
Reijn TS; Rikkert MO; van Geel WJ; de Jong D; Verbeek MM
Clin Chem; 2007 May; 53(5):859-65. PubMed ID: 17395712
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.
Olsson A; Vanderstichele H; Andreasen N; De Meyer G; Wallin A; Holmberg B; Rosengren L; Vanmechelen E; Blennow K
Clin Chem; 2005 Feb; 51(2):336-45. PubMed ID: 15563479
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
4. Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease.
Wang LS; Leung YY; Chang SK; Leight S; Knapik-Czajka M; Baek Y; Shaw LM; Lee VM; Trojanowski JQ; Clark CM
J Alzheimers Dis; 2012; 31(2):439-45. PubMed ID: 22571982
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia.
Nägga K; Gottfries J; Blennow K; Marcusson J
Dement Geriatr Cogn Disord; 2002; 14(4):183-90. PubMed ID: 12411760
[TBL] [Abstract][Full Text] [Related]
6. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.
Mulder C; Verwey NA; van der Flier WM; Bouwman FH; Kok A; van Elk EJ; Scheltens P; Blankenstein MA
Clin Chem; 2010 Feb; 56(2):248-53. PubMed ID: 19833838
[TBL] [Abstract][Full Text] [Related]
8. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms.
Irwin DJ; McMillan CT; Toledo JB; Arnold SE; Shaw LM; Wang LS; Van Deerlin V; Lee VM; Trojanowski JQ; Grossman M
Arch Neurol; 2012 Aug; 69(8):1018-25. PubMed ID: 22490326
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.
Kang JH; Korecka M; Toledo JB; Trojanowski JQ; Shaw LM
Clin Chem; 2013 Jun; 59(6):903-16. PubMed ID: 23519967
[TBL] [Abstract][Full Text] [Related]
11. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
Shaw LM; Vanderstichele H; Knapik-Czajka M; Figurski M; Coart E; Blennow K; Soares H; Simon AJ; Lewczuk P; Dean RA; Siemers E; Potter W; Lee VM; Trojanowski JQ;
Acta Neuropathol; 2011 May; 121(5):597-609. PubMed ID: 21311900
[TBL] [Abstract][Full Text] [Related]
12. CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics.
Jeppsson A; Wikkelsö C; Blennow K; Zetterberg H; Constantinescu R; Remes AM; Herukka SK; Rauramaa T; Nagga K; Leinonen V; Tullberg M
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1117-1123. PubMed ID: 31167811
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging.
Lim HJ; Park JE; Kim BC; Choi SM; Song MK; Cho SH; Seo HJ; Kim J; Song HC; Choi KY; Lee JJ; Kim HW; Ha JM; Song WK; Park SG; Lee JS; Lee KH
J Alzheimers Dis; 2020; 75(3):949-958. PubMed ID: 32390627
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis.
Agnello L; Piccoli T; Vidali M; Cuffaro L; Lo Sasso B; Iacolino G; Giglio VR; Lupo F; Alongi P; Bivona G; Ciaccio M
Scand J Clin Lab Invest; 2020 Jul; 80(4):313-317. PubMed ID: 32255379
[TBL] [Abstract][Full Text] [Related]
15. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.
de Jong D; Jansen RW; Kremer BP; Verbeek MM
J Gerontol A Biol Sci Med Sci; 2006 Jul; 61(7):755-8. PubMed ID: 16870640
[TBL] [Abstract][Full Text] [Related]
17. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.
Laske C; Stransky E; Fritsche A; Eschweiler GW; Leyhe T
Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):80-5. PubMed ID: 18806919
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
[TBL] [Abstract][Full Text] [Related]
19. LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia.
Le Bastard N; Van Buggenhout M; De Leenheir E; Martin JJ; De Deyn PP; Engelborghs S
J Gerontol A Biol Sci Med Sci; 2007 Aug; 62(8):923-4; author reply 924-5. PubMed ID: 17702886
[No Abstract] [Full Text] [Related]
20. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.
Schoonenboom NS; Pijnenburg YA; Mulder C; Rosso SM; Van Elk EJ; Van Kamp GJ; Van Swieten JC; Scheltens P
Neurology; 2004 May; 62(9):1580-4. PubMed ID: 15136685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
